Xanthine oxidase-IN-4

Cat. No.: HY-144303: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC₅₀ of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research.

For research use only. We do not sell to patients.

Xanthine oxidase-IN-4 Chemical Structure

CAS No. : 2642137-96-8

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC₅₀: 0.039 μM (xanthine oxidase)^[1]

In Vitro

Xanthine oxidase-IN-4 (compound 19a) (1 nM-10 μM, 15 min) exhibits a strong XO inhibitory potency, with an IC₅₀ of 0.039 μM, and Ki of 0.0037 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Xanthine oxidase-IN-4 (compound 19a) (SD rats, 10 mg/kg, Intragastrically, once) significantly reduces the serum concentration of uric acid^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley rats (Six weeks, male, 180-200g, six groups)^[1]
Dosage:	10 mg/kg
Administration:	Intragastrically, once
Result:	Significantly reduced the serum concentration of uric acid, with AUC (uric acid, 1-5 h) of 44.3%.

Molecular Weight

295.30

Formula

C₁₅H₁₃N₅O₂

CAS No.

2642137-96-8

SMILES

N#CC1=CC(C2=NC=C3C(NNC3=O)=N2)=CC=C1OC(C)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Zhao J, et al. Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors. Eur J Med Chem. 2022;229:114086. [Content Brief]